DOSINDYGO: DOSe finding for INtraoperative photoDYnamic therapy of GliOblastoma

C. Dupont; F. Lecomte; P. Deleporte; G. Baert; S. Mordon; N. Reyns; M. Vermandel

doi:10.1117/12.2524949

7 August 2019 DOSINDYGO: DOSe finding for INtraoperative photoDYnamic therapy of GliOblastoma

C. Dupont, F. Lecomte, P. Deleporte, G. Baert, S. Mordon, N. Reyns, M. Vermandel

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 1107064 (2019) https://doi.org/10.1117/12.2524949
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

Glioblastoma is a malignant brain tumor with a poor prognosis. Currently, complete resection is rarely feasible, since tumor cells usually infiltrate the surrounding brain. Recently, the INDYGO clinical trial has been achieved to assess the toxicity of photodynamic therapy (PDT) delivered intraoperatively to treat newly diagnosed glioblastoma. Today, we believe that the PDT effect obtained in the INDYGO clinical trial can be improved by a higher light dose. The DOSINDYGO clinical trial aims to achieve a light-dose escalation increasing up to four times the initial light dose used in the INDYGO trial. An increase of both light power and treatment time should allow to treat deeper in the surrounding tissues (up to 8mm) and thus decrease the recurrence risk. First light dose will be reached by doubling the treatment time used in the INDYGO trial, the other one will be achieved by increasing light power only. This methodology was chosen in order to maintain an acceptable treatment time for anesthesia but also to prevent higher fluence rate that could induce a lower tolerance as observed in our preclinical results. Primary endpoint will be to determine the optimum light-dose regarding the ratio efficacy and tolerance of the treatment. Primary criterion is the assessment of the progression free survival within the bed border’s cavity. Finally, although no adverse effect has been noticed during the INDYGO trial, increasing light dose in this DOSINDYGO trial could result in other direct and indirect biological effects.

Citation Download Citation

C. Dupont, F. Lecomte, P. Deleporte, G. Baert, S. Mordon, N. Reyns, and M. Vermandel "DOSINDYGO: DOSe finding for INtraoperative photoDYnamic therapy of GliOblastoma", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 1107064 (7 August 2019); https://doi.org/10.1117/12.2524949

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
3 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Photodynamic therapy

Tumors

Clinical trials

Brain

Therapeutics

Tissues

Oxygen

Show All Keywords

Keywords/Phrases

Search In:

Publication Years